Allurion appoints former life sciences interim CEO to expanding board of directors
Image I Courtesy of Google Images
Allurion Technologies is located at 11 Huron Dr. in Natick.
Weight-loss tech company Allurion Technologies has expanded its board of directors, appointing Jason Richey on Dec. 30 as the Natick publicly traded company’s ninth member.
Richey works as an independent consultant to RTW Investments, a New York City-based life sciences investment firm. A stockholder in the company, Richey consults on portfolio clients with RTW, according to a Monday filing from Allurion with the U.S. Securities and Exchange Commission.
Prior to his current roles, Richey held a number of C-suite positions throughout the past five years. Richey has served as president and CEO of Woburn-based medical technology company Cytrellis Biosystems and in several positions at Canada-based aesthetics device company Cutera, including president, COO, and interim CEO.
He finished his 17-year tenure with Cyberonics as president of its North American operations, before the medical device company merged with London manufacturer LivaNova.
Richey graduated with his bachelor’s degree in biology from Indiana University.
Allurion became a publicly traded company on the New York Stock Exchange on Aug. 2, 2023, after receiving approval for a business combination with Delaware-based Compute Health Acquisition two days prior.
With $661,226 in total compensation in fiscal 2023, Allurion’s CEO Shantanu Gaur is the 16th highest paid CEO in Central Massachusetts, according to data collected by WBJ’s Research Department.
Mica Kanner-Mascolo is a staff writer at Worcester Business Journal, who primarily covers the healthcare and diversity, equity, and inclusion industries.
WBJ Web Partners
Most Recent
Most Recent
0 Comments